Climb Bio (CLYM) Other Non-Current Assets (2020 - 2026)
Climb Bio's (CLYM) quarterly Other Non-Current Assets came in at $1.5 million in Q1 2026, up 576.99% YoY from $226000.0 in Q1 2025, and little changed on a QoQ basis from $1.5 million in Q4 2025.
Climb Bio (CLYM) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Other Non-Current Assets data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 576.99% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 576.99% YoY) and the FY2025 annual result came in at $1.5 million, up 9462.5% from the prior year.
- Other Non-Current Assets held at $1.5 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $4.6 million in Q2 2022 to a low of $15000.0 in Q2 2023.
- A 5-year average of $853187.5 and a median of $505500.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets plunged 99.68% — and 2025, when it surged 9462.5%.
- Tracing CLYM's Other Non-Current Assets over 5 years: stood at $456000.0 in 2022, then slumped by 96.71% to $15000.0 in 2023, then advanced by 6.67% to $16000.0 in 2024, then surged by 9462.5% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.65 Mn |
| Mar 31, 2026 | 1.53 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 226,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Sep 30, 2024 | 361,000.00 |
| Mar 31, 2024 | 625,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Sep 30, 2023 | 15,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | 178,000.00 |
| Dec 31, 2022 | 456,000.00 |
| Sep 30, 2022 | 555,000.00 |
| Jun 30, 2022 | 4.63 Mn |
| Mar 31, 2022 | 600,000.00 |
| Dec 31, 2021 | 70,000.00 |
| Jun 30, 2021 | 458,000.00 |
| Dec 31, 2020 | 2.63 Mn |